Longeveron FY2025 EPS Forecast Reduced by Zacks Small Cap

Longeveron Inc. (NASDAQ:LGVN) – Research analysts at Zacks Small Cap cut their FY2025 EPS estimates for Longeveron in a note issued to investors on Monday, March 3rd. Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings of ($1.84) per share for the year, down from their prior forecast of ($1.28). The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share.

LGVN has been the subject of a number of other research reports. Roth Capital raised Longeveron to a “strong-buy” rating in a research report on Thursday, December 5th. Roth Mkm began coverage on Longeveron in a report on Friday, December 6th. They issued a “buy” rating and a $10.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Longeveron in a research note on Monday.

Longeveron Stock Performance

LGVN stock opened at $1.33 on Wednesday. The company has a 50 day moving average price of $1.65 and a two-hundred day moving average price of $1.90. The stock has a market capitalization of $19.73 million, a P/E ratio of -0.21 and a beta of 0.36. Longeveron has a one year low of $0.77 and a one year high of $6.40.

Institutional Trading of Longeveron

Several institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC raised its position in shares of Longeveron by 316.0% in the 3rd quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock worth $250,000 after buying an additional 97,953 shares during the period. Virtu Financial LLC acquired a new stake in Longeveron during the fourth quarter worth about $53,000. Jane Street Group LLC purchased a new position in shares of Longeveron in the 4th quarter worth about $35,000. Northern Trust Corp acquired a new position in shares of Longeveron in the 4th quarter valued at about $31,000. Finally, State Street Corp acquired a new position in shares of Longeveron in the 3rd quarter valued at about $29,000. 10.01% of the stock is owned by hedge funds and other institutional investors.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.